Ursodeoxycholic acid 'mechanisms of action and clinical use in hepatobiliary disorders'. (Q34330984)

1 August 2017

1 reference

title

Ursodeoxycholic acid 'mechanisms of action and clinical use in hepatobiliary disorders'. (English)

1 reference

1 August 2017

K N Lazaridis

1

1 reference

1 August 2017

G J Gores

series ordinal

2

1 reference

1 August 2017

K D Lindor

series ordinal

3

1 reference

1 August 2017

publication date

1 July 2001

1 reference

1 August 2017

published in

Journal of Hepatology

1 reference

1 August 2017

volume

35

1 reference

1 August 2017

issue

1

1 reference

1 August 2017

page(s)

134-146

1 reference

Ursodeoxycholic acid in the treatment of cholesterol cholelithiasis. part I

1 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900092-7

7 January 2021

Gallstone dissolution with ursodeoxycholic acid in patients with chronic active hepatitis and two years follow-up. A pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900092-7

7 January 2021

Is ursodeoxycholic acid an effective treatment for primary biliary cirrhosis?

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900092-7

7 January 2021

Pharmacology of ursodeoxycholic acid, an enterohepatic drug.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900092-7

7 January 2021

Ursodiol for hepatobiliary disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900092-7

7 January 2021

Primary Biliary Cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900092-7

7 January 2021

Effect of cholestyramine on bile acid pattern and synthesis during administration of ursodeoxycholic acid in man.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900092-7

7 January 2021

Influence of cholestasis on absorption of ursodeoxycholic acid

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900092-7

7 January 2021

Hepatic transport of bile salts

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900092-7

7 January 2021

Ursodeoxycholic acid in the treatment of liver diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900092-7

7 January 2021

Ursodeoxycholic acid: a review of its pharmacological properties and therapeutic efficacy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900092-7

7 January 2021

Cholesterol-lowering effect of ursodeoxycholic acid in patients with primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900092-7

7 January 2021

Ursodeoxycholic acid therapy of chronic cholestatic conditions in adults and children

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900092-7

7 January 2021

Mechanism of hepatoprotective action of bile salts in liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900092-7

7 January 2021

Hepatoprotective properties of ursodeoxycholic acid

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900092-7

7 January 2021

Effect of ursodeoxycholic acid on the kinetics of the major hydrophobic bile acids in health and in chronic cholestatic liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900092-7

7 January 2021

Effect of ursodeoxycholic acid on the kinetics of cholic acid and chenodeoxycholic acid in patients with primary sclerosing cholangitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900092-7

7 January 2021

Review article: mechanisms of action and therapeutic applications of ursodeoxycholic acid in chronic liver diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900092-7

7 January 2021

Kinetics of hepatic bile acid handling in cholestatic liver disease: effect of ursodeoxycholic acid.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900092-7

7 January 2021

Effects of tauroursodeoxycholic acid on cytosolic Ca2+ signals in isolated rat hepatocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900092-7

7 January 2021

Tauroursodeoxycholic acid stimulates hepatocellular exocytosis and mobilizes extracellular Ca++ mechanisms defective in cholestasis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900092-7

7 January 2021

Tauroursodeoxycholic acid activates protein kinase C in isolated rat hepatocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900092-7

7 January 2021

Mitogen-activated protein kinases mediate the stimulation of bile acid secretion by tauroursodeoxycholate in rat liver

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900092-7

7 January 2021

Abnormal expression of anion exchanger genes in primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900092-7

7 January 2021

Decreased anion exchanger 2 immunoreactivity in the liver of patients with primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900092-7

7 January 2021

Ursodeoxycholate increases cytosolic calcium concentration and activates CI− currents in a biliary cell line

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900092-7

7 January 2021

Effect of side-chain shortening on the physiologic properties of bile acids: hepatic transport and effect on biliary secretion of 23-nor-ursodeoxycholate in rodents.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900092-7

7 January 2021

Inhibition of Na+/H+ exchange in the rat is associated with decreased ursodeoxycholate hypercholeresis, decreased secretion of unconjugated urodeoxycholate, and increased ursodeoxycholate glucuronidation.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900092-7

7 January 2021

Rat cholangiocytes absorb bile acids at their apical domain via the ileal sodium-dependent bile acid transporter

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900092-7

7 January 2021

Alternative splicing of the rat sodium/bile acid transporter changes its cellular localization and transport properties

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900092-7

7 January 2021

ATP-dependent transport of bile salts by rat multidrug resistance-associated protein 3 (Mrp3)

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900092-7

7 January 2021

Immunomodulatory effects of ursodeoxycholic acid on immune responses

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900092-7

7 January 2021

Bile acids with differing hydrophilic-hydrophobic properties do not influence cytokine production by human monocytes and murine Kupffer cells

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900092-7

7 January 2021

A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900092-7

7 January 2021

Ursodeoxycholic acid treatment lowers the serum level of antibodies against pyruvate dehydrogenase and influences their inhibitory capacity for the enzyme complex in patients with primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900092-7

7 January 2021

Increased expression of major histocompatibility antigens in the liver as a result of cholestasis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900092-7

7 January 2021

Aberrant expression of HLA-DR antigens on bileduct epithelium in primary biliary cirrhosis: relevance to pathogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900092-7

7 January 2021

Effects of bile acids and cholestasis on major histocompatibility complex class I in human and rat hepatocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900092-7

7 January 2021

Hepatic expression of class I and class II major histocompatibility complex molecules in primary biliary cirrhosis: effect of ursodeoxycholic acid

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900092-7

7 January 2021

Effect of cholestasis and bile acids on interferon-induced 2′, 5′-adenylate synthetase and NK cell activities

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900092-7

7 January 2021

Ursodeoxycholic acid corrects defective natural killer activity by inhibiting prostaglandin E2 production in primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900092-7

7 January 2021

Ursodeoxycholic acid inhibits eosinophil degranulation in patients with primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900092-7

7 January 2021

Immunosuppressive properties of chenodeoxycholic and ursodeoxycholic acids in the mouse

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900092-7

7 January 2021

Conjugates of ursodeoxycholate protect against cytotoxicity of more hydrophobic bile salts: in vitro studies in rat hepatocytes and human erythrocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900092-7

7 January 2021

Ursodeoxycholate conjugates protect against disruption of cholesterol-rich membranes by bile salts.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900092-7

7 January 2021

Effects of Ursodeoxycholate and cholate feeding on liver disease in FVB mice with a disrupted mdr2 P-glycoprotein gene.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900092-7

7 January 2021

Stereological and functional analysis of liver mitochondria from rats with secondary biliary cirrhosis: impaired mitochondrial metabolism and increased mitochondrial content per hepatocyte

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900092-7

7 January 2021

Ursodeoxycholic acid may inhibit deoxycholic acid-induced apoptosis by modulating mitochondrial transmembrane potential and reactive oxygen species production

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900092-7

7 January 2021

Cell death by apoptosis: basic concepts and disease relevance for the gastroenterologist

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900092-7

7 January 2021

Toxic bile salts induce rodent hepatocyte apoptosis via direct activation of Fas.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900092-7

7 January 2021

Enhanced apoptosis relates to bile duct loss in primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900092-7

7 January 2021

A novel role for ursodeoxycholic acid in inhibiting apoptosis by modulating mitochondrial membrane perturbation

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900092-7

7 January 2021

Is ursodeoxycholate an antiapoptotic drug?

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900092-7

7 January 2021

Ursodiol for the long-term treatment of primary biliary cirrhosis. The UDCA-PBC Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900092-7

7 January 2021

Effects of ursodeoxycholic acid on survival in patients with primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900092-7

7 January 2021

Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900092-7

7 January 2021

Cost-effectiveness of ursodeoxycholic acid therapy in primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900092-7

7 January 2021

A randomized trial comparing colchicine and ursodeoxycholic acid combination to ursodeoxycholic acid in primary biliary cirrhosis. UDCA-PBC Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900092-7

7 January 2021

Ursodeoxycholic acid and prednisolone versus ursodeoxycholic acid and placebo in the treatment of early stages of primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900092-7

7 January 2021

The combination of ursodeoxycholic acid and methotrexate for primary biliary cirrhosis is not better than ursodeoxycholic acid alone

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900092-7

7 January 2021

Triple therapy with ursodeoxycholic acid, prednisone and azathioprine in primary biliary cirrhosis: a 1-year randomized, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900092-7

7 January 2021

Randomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900092-7

7 January 2021

URSO-panacea or placebo?

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900092-7

7 January 2021

Management of primary biliary cirrhosis. The American Association for the Study of Liver Diseases practice guidelines

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900092-7

7 January 2021

Ursodeoxycholic acid for primary sclerosing cholangitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900092-7

7 January 2021

Ursodeoxycholic acid for the treatment of primary sclerosing cholangitis: a 30-month pilot study.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900092-7

7 January 2021

Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900092-7

7 January 2021

Effect of ursodeoxycholic acid on liver and bile duct disease in primary sclerosing cholangitis. A 3-year pilot study with a placebo-controlled study period

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900092-7

7 January 2021

Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900092-7

7 January 2021

Effects of ursodeoxycholic acid in patients with intrahepatic cholestasis of pregnancy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900092-7

7 January 2021

Ursodeoxycholic acid in the treatment of cholestasis of pregnancy: a randomized, double-blind study controlled with placebo

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900092-7

7 January 2021

Progesterone metabolites and bile acids in serum of patients with intrahepatic cholestasis of pregnancy: effect of ursodeoxycholic acid therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900092-7

7 January 2021

Ursodeoxycholic acid administration in patients with cholestasis of pregnancy: effects on primary bile acids in babies and mothers

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900092-7

7 January 2021

Liver cirrhosis in cystic fibrosis--therapeutic implications and long term follow up.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900092-7

7 January 2021

Effects of ursodeoxycholic acid treatment on nutrition and liver function in patients with cystic fibrosis and longstanding cholestasis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900092-7

7 January 2021

Effects of ursodeoxycholic acid therapy for liver disease associated with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900092-7

7 January 2021

Ursodeoxycholic acid for liver disease associated with cystic fibrosis: a double-blind multicenter trial. The Italian Group for the Study of Ursodeoxycholic Acid in Cystic Fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900092-7

7 January 2021

A two-year prospective study of the effect of ursodeoxycholic acid on urinary bile acid excretion and liver morphology in cystic fibrosis-associated liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900092-7

7 January 2021

Ursodeoxycholic acid therapy in cystic fibrosis-associated liver disease: a dose-response study.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900092-7

7 January 2021

Low-dose versus high-dose ursodeoxycholic acid in cystic fibrosis-related cholestatic liver disease. Results of a randomized study with 1-year follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900092-7

7 January 2021

Ursodeoxycholic acid therapy in pediatric patients with progressive familial intrahepatic cholestasis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900092-7

7 January 2021

Treatment with ursodeoxycholic acid renders children with biliary atresia suitable for liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900092-7

7 January 2021

Ursodeoxycholic acid: a safe and effective agent for dissolving cholesterol gallstones

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900092-7

7 January 2021

Gallstone recurrence after successful oral bile acid treatment. A 12-year follow-up study and evaluation of long-term postdissolution treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900092-7

7 January 2021

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900092-7

1 reference

7 January 2021

Ursodeoxycholic acid treatment of refractory chronic graft-versus-host disease of the liver

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900092-7

7 January 2021

Hepatic GVHD after HLA-haploidentical bone marrow transplantation in children with severe combined immunodeficiency: the effect of ursodeoxycholic acid

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900092-7

7 January 2021

Ursodiol prophylaxis against hepatic complications of allogeneic bone marrow transplantation. A randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900092-7

7 January 2021

Failure of ursodeoxycholic acid to prevent acute cellular rejection after liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900092-7

7 January 2021

The Nordic multicenter double-blind randomized controlled trial of prophylactic ursodeoxycholic acid in liver transplant patients

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900092-7

7 January 2021

A randomized clinical trial of ursodeoxycholic acid as adjuvant treatment to prevent liver transplant rejection.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900092-7

7 January 2021

A prospective, randomized, double-blind trial evaluating the efficacy of ursodeoxycholic acid in prevention of liver transplant rejection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900092-7

7 January 2021

Chlorpromazine-induced vanishing bile duct syndrome leading to biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900092-7

7 January 2021

Effective treatment of cyclosporine-induced cholestasis in heart-transplanted patients treated with ursodeoxycholic acid

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900092-7

7 January 2021

Cholestasis associated with total parenteral nutrition in infants.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900092-7

7 January 2021

Ursodeoxycholic acid for treatment of cholestasis in children on long-term total parenteral nutrition: a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900092-7

7 January 2021

Intravenous ursodeoxycholic acid reduces cholestasis in parenterally fed newborn piglets

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900092-7

7 January 2021

Efficacy of ursodeoxycholic acid in preventing cholestatic episodes in a patient with benign recurrent intrahepatic cholestasis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900092-7

7 January 2021

Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900092-7

7 January 2021

Effect of tauroursodeoxycholic and ursodeoxycholic acid on ethanol-induced cell injuries in the human Hep G2 cell line.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900092-7

7 January 2021

Ursodeoxycholate protects against ethanol-induced liver mitochondrial injury

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900092-7

7 January 2021

Ursodiol in the long-term treatment of chronic hepatitis: a double-blind multicenter clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900092-7

7 January 2021

Interferon and ursodeoxycholic acid combined therapy in chronic viral C hepatitis: controlled randomized trial in 203 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900092-7

7 January 2021

Ursodeoxycholic acid as adjunctive therapy for problematic type 1 autoimmune hepatitis: a randomized placebo-controlled treatment trial

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900092-7

7 January 2021

10.1016/S0168-8278(01)00092-7

Identifiers

DOI

1 reference

1 August 2017

1 reference